
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

QingSong Health inks agreement with Basel Medical to explore AI healthcare services in Southeast Asia

June 10, 2026 | News

To explore new growth opportunities in cross-border healthcare



China-based QingSong Health Corp and Basel Medical Group have announced the signing of a Memorandum of Strategic Cooperation. The two parties intend to explore cooperation in artificial intelligence (AI)-enabled healthcare services, insurance-related healthcare solutions, and cross-border medical services in Southeast Asia.

Under the memorandum, QingSong Health Corp plans to leverage its AIcare technology stack and its evidence-based medical AI agent system, QSevidence, while Basel Medical Group will contribute its specialist healthcare service scenarios and enterprise client network in Singapore and Southeast Asia.

The cooperation is expected to focus on two main areas.

First, the parties will explore ways to enhance Basel Medical Group's existing healthcare services through AI. Potential applications include AI-supported clinical decision support and physician training, AI agents for patient services such as appointment booking, consultation support and follow-up management, as well as AI applications in insurance claims and underwriting assessment.

Second, the parties plan to explore new growth opportunities in cross-border healthcare. By combining QingSong Health Corp's cross-border healthcare capabilities with Basel Medical Group's position in Singapore, the two companies aim to develop a service corridor connecting China and Southeast Asia's specialist medical networks.

Headquartered in Singapore, Basel Medical Group is a specialist healthcare services group. According to its public filings, the company provides general and subspecialised orthopedic and trauma services, sports medicine and surgery, orthopedic

procedures, and neurosurgical treatments.